Latest Licensing News

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Singular Health boosted its US presence by deploying 500 additional 3DICOM MD® licenses to Provider Network Solutions, securing FDA 510(k) clearance for its cloud platform, and launching education pilots with Miami-Dade schools and Florida International University.

Firebird Metals has locked in exclusive global rights to key LMFP patents through 2045 and commissioned lithium-manganese-rich cathode equipment, progressing its Australian Demonstration Plant with a $2 million ARENA grant.

Raiden Resources is pushing forward with its Crixás Gold Tailings Project in Brazil, planning a 1,000m drilling program to establish a JORC Mineral Resource Estimate and aiming for a Final Investment Decision with less than A$1 million in preliminary costs. Meanwhile, exploration at its Vuzel Gold Project in Bulgaria progresses with permitting for a silver anomaly drill program.

Sarytogan Graphite Limited has upgraded its Central Graphite Zone resource, marking a key milestone with Measured classification and progressing its Definitive Feasibility Study. Meanwhile, copper exploration reveals promising anomalies, backed by fresh capital injections.

InFocus Group Holdings has launched Codexa, a proprietary sweepstakes casino platform targeting the US market, and secured an expanded contract for its Prodigy9 subsidiary in Thailand, while navigating cash flow pressures amid ongoing R&D investment.

Temas Resources has closed a CAD 1.5 million flow-through share placement with Maple Leaf Critical Minerals Fund, reinforcing funding for its Quebec titanium projects and proprietary Regenerative Chloride Leach technology commercialisation.

Fortescue Ltd has greenlit a US$680 million expansion of its Pilbara renewable energy infrastructure, aiming to deliver 200MW of additional capacity by 2028 to meet rising industrial and data centre demand while advancing its Real Zero by 2030 emissions target.

Rapid Critical Metals has reshaped its leadership and strategy in FY2025, positioning itself as a silver and rare earths contender with well-funded drilling programs in Australia and Canada.

Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.

BPH Global’s Indonesian arm has entered Stage 2 of its collaboration with Indonesia’s National Research and Innovation Agency to develop fucoidan extraction technology and a powdered supplement prototype, targeting commercialisation within months.

Adisyn Ltd has landed a A$14 million placement led by heavyweight institutional investors following two major graphene technology milestones in semiconductors and stealth drone materials.